Peptide Therapy: A Physician's Honest Assessment of What Works, What's Hype, and What's Changing in 2026
Dr. RP, MD — Board-Certified, Emergency Medicine & Critical Care Medicine — Founder, Analog Precision Medicine
In two decades of emergency and critical care medicine, I have watched dozens of wellness trends rise and fall. Most are harmless. A few — like the peptide injections at a Las Vegas anti-aging festival last summer that put two attendees in the ICU on ventilators — are not. Peptide therapy is the trend patients ask me about most often right now, and the gap between what they have been told and what the evidence actually supports is wider than nearly any other category in modern wellness medicine.
This is the version of that conversation I have with patients in my South Bay practice — what is legitimate, what is hype, and what the FDA's April 2026 reclassification actually means. Dr. William Meller wrote a sharp recent piece on this same gold rush that I would recommend reading alongside this one — several of his specific clinical points appear below with credit.
What Counts as a Peptide
Peptides are short chains of amino acids — biological signaling molecules. The category is real, productive, and includes some of the most important drugs in modern medicine: insulin, oxytocin, the GLP-1 agonists semaglutide and tirzepatide. There are more than 100 FDA-approved peptide drugs on the market. Anyone who tells you the FDA is categorically hostile to peptides is wrong.
The compounds being sold by anti-aging clinics, telehealth peptide vendors, and Instagram coaches are a narrow and largely unstudied subset of this category. The marketing pitch is often that these compounds are “natural” because the body produces similar molecules. They are not natural. As Meller points out, synthetic peptides are deliberately engineered to last longer in the bloodstream than the body's own peptides — that is the entire point of the modification. A chemically tweaked, enzyme-resistant compound ordered from an overseas supplier is not a holistic remedy. It is pharmacology, often without the trial data.
The Evidence Hierarchy
Tier A — Real evidence, real FDA history
Sermorelin
A GHRH analog. FDA-approved as a diagnostic in 1990 and for pediatric growth hormone deficiency in 1997. The manufacturer voluntarily discontinued it in 2008 for commercial — not safety — reasons. Adult studies show it can restore the age-related decline in growth hormone and IGF-1 (Corpas et al., 1992; Sigalos et al., 2018). Currently legal to compound with a valid prescription. The only growth hormone secretagogue I would consider prescribing today.
Tesamorelin (Egrifta)
A GHRH analog with the strongest Phase 3 data of any peptide in this article — for a narrow FDA indication: visceral fat reduction in HIV-associated lipodystrophy. The newest formulation, Egrifta WR, was FDA-approved in March 2025; cash price runs upwards of $10,000 per month. Compounded versions are widely advertised by longevity-adjacent telehealth services at a fraction of that price — which deserves a flag, because tesamorelin was reclassified as a biologic under federal law in 2020 and is therefore not eligible for legal 503A compounding. Compounded tesamorelin operates on selective FDA non-enforcement, not the same legal footing as compounded sermorelin. Real medicine for the right HIV patient and possibly an option for non-HIV patients who need, but don't tolerate, Sermorelin. Not a generalist longevity peptide.
PT-141 (Bremelanotide / Vyleesi)
FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women. Two Phase 3 trials enrolling roughly 1,200 women (RECONNECT) met their primary endpoints (Kingsberg et al., 2019). Acts centrally via brain melanocortin pathways rather than peripherally like sildenafil. Smaller but legitimate off-label data in men (Safarinejad, 2010). Compounded versions, including intranasal, are widely available.
Elamipretide (Forzinity / SS-31)
A mitochondria-targeted peptide that received FDA accelerated approval in September 2025 — the first mitochondria-targeted therapeutic ever approved. Indication: improving muscle strength in Barth syndrome, an ultra-rare genetic mitochondrial disease affecting roughly 150 patients in the United States. Worth understanding what the trial data actually showed: in the randomized portion of the pivotal TAZPOWER trial, elamipretide was not superior to placebo on the primary endpoints (six-minute walk test and fatigue score). Accelerated approval came on a secondary endpoint of knee extensor strength. Longevity clinics are now marketing elamipretide off-label for general “mitochondrial health” and “cellular energy” — claims with no Phase 3 support outside Barth syndrome. Real medicine for an ultra-rare disease. Not, today, a generalist longevity peptide.
GHK-Cu (topical)
A copper-binding tripeptide with decades of dermatologic data showing real effects on collagen density and skin elasticity. Topical formulations are legal and reasonable. Injectable orthopedic claims are speculative.
GLP-1 / GIP agonists (semaglutide, tirzepatide)
Multiple Phase 3 RCTs. FDA-approved. The most consequential peptide-class drugs of the last decade. Mention here because patients sometimes do not realize Ozempic, Wegovy, Mounjaro, and Zepbound are peptides — they are, and they are excellent medicine.
Tier B — Plausible biology, thin or non-Western human data
CJC-1295 plus Ipamorelin
A growth-hormone-secretagogue combination popular in longevity clinics. Biology plausible. Human data limited to small pharmacokinetic studies (Ionescu and Frohman, 2006). No randomized controlled trials for body composition, recovery, or longevity endpoints. Both peptides removed from FDA Category 2 in September 2024; under PCAC review. Worth flagging that long-term GH secretagogue use carries documented acromegaly risk — pathological enlargement of bones and organs from chronic GH excess.
Tier C — Animal data, almost nothing in humans
BPC-157
“The Wolverine peptide.” A 2025 systematic review in HSS Journal cataloged 36 animal studies showing tissue-healing effects across muscle, tendon, and ligament injury models (Vasireddi et al., 2025). The total human dataset is three small studies — none of them randomized controlled trials. The Atria Institute, Peter Attia's longevity practice, characterizes BPC-157's human safety data as “extremely limited.” Meller raises a specific clinical concern worth foregrounding: BPC-157 promotes angiogenesis, the formation of new blood vessels. Useful for tendon repair. Less useful given that early-stage occult cancers also depend on angiogenesis to grow. A patient injecting an unapproved angiogenic compound has no way of knowing whether they are healing a joint or feeding a tumor.
TB-500
A synthetic fragment of thymosin beta-4. Promising preclinical work in tendon healing. Zero human orthopedic data. Heavily used in equine veterinary medicine.
Tier D — Hard pass
AOD-9604
Failed its Phase 2b obesity trial. Could not beat placebo. Still aggressively sold online. No defensible reason to prescribe a peptide that lost to a sugar pill.
MK-677 (Ibutamoren)
Oral, convenient, consistently associated with insulin resistance and elevated fasting glucose. Antithetical to a metabolic optimization practice.
Melanotan II
Real melanoma concerns and a recreational misuse profile.
Anything from a “research chemical” vendor
Sold with “not for human use” labels and injected by patients anyway. Independent testing has documented endotoxin contamination, mislabeling, and absence of the labeled compound. The Las Vegas ICU admissions came from this part of the market.
What Changed on April 15, 2026
In September 2023, the FDA placed 19 peptides on Category 2 of its 503A interim bulks list, effectively banning their compounding. After legal challenges and an HHS-level intervention, the FDA on April 15, 2026, removed twelve peptides from Category 2: BPC-157, LL-37, DiHexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500.
Removal from Category 2 is not the same as legal to compound. Each compound still requires Pharmacy Compounding Advisory Committee (PCAC) review, which can recommend addition to the 503A bulks list, return to Category 2, or move to a “needs more study” Category 3.
PCAC Schedule
Realistic earliest legal compounding window for BPC-157 and TB-500: late summer to early fall 2026, and only if PCAC recommends and the FDA acts. Some pharmacies will resume production immediately on the Category 2 removal alone. Others will wait for formal 503A list addition.
What We Are Doing at Analog Precision Medicine
Available now
Sermorelin for appropriate candidates with documented decline in the growth hormone axis. PT-141 where the indication and evidence support its use. Topical GHK-Cu for skin and collagen.
Deliberately on hold
BPC-157, TB-500, and the rest of the regenerative panel — until they are available through legitimate 503A pharmacies sourcing from FDA-registered API manufacturers, with proper informed consent.
Not on the menu, ever
AOD-9604. MK-677. Melanotan II. Compounded tesamorelin in the legal gray zone. Anything from a research chemical vendor. Anything injected by a non-physician at a longevity conference.
Reference Table
| Peptide | What It Targets | Evidence | Regulatory Status |
|---|---|---|---|
| Tier A — Real evidence, FDA approval | |||
| Sermorelin | GH axis | FDA-approved (pediatric GHD); adult studies | Compoundable |
| Tesamorelin (Egrifta WR) | Visceral fat (HIV) | Phase 3 (narrow indication) | Brand-name; ~$10K/mo |
| PT-141 (Vyleesi) | Sexual desire | Phase 3 RCTs; FDA-approved 2019 | Brand + compounded |
| Topical GHK-Cu | Skin / collagen | Decades dermatologic | Available |
| GLP-1 / GIP agonists | Diabetes / weight | Multiple Phase 3 RCTs | Brand-name |
| Elamipretide (Forzinity) | Mitochondrial (Barth) | FDA-approved Sept 2025 | Brand; ultra-rare indication |
| Tier B — Real human data, narrower or non-Western | |||
| Thymosin Alpha-1 | Immune | Approved in 30+ countries (Zadaxin) | Cat 2 in US |
| Cerebrolysin | Stroke / cognition | RCTs; approved in 50+ countries | Not FDA-approved |
| ARA-290 (Cibinetide) | Neuropathy | Phase II RCTs positive | Investigational |
| Kisspeptin-10 | HPG axis | Multiple human trials | Investigational |
| CJC-1295 + Ipamorelin | GH stack | Small PK studies | Removed Cat 2; PCAC review |
| Tier C — Animal data, vanishingly little in humans | |||
| BPC-157 | Tissue repair | 36 animal studies; 3 small human | Cat 2 → PCAC July 2026 |
| TB-500 | Tissue repair | Animal / equine data | Cat 2 → PCAC July 2026 |
| KPV | Anti-inflammatory | Mostly preclinical | Cat 2 → PCAC July 2026 |
| Injectable GHK-Cu | Tissue repair | Speculative beyond skin | Cat 2 → PCAC Feb 2027 |
| FOXO4-DRI | Senolytic | Preclinical only | Investigational |
| Tier D — Avoid | |||
| AOD-9604 | Fat loss | Failed Phase 2b trial | Avoid |
| MK-677 | Oral GH | Insulin resistance | Avoid |
| Melanotan II | Tanning | Melanoma concerns | Avoid |
| Research-chemical anything | Various | None | ER visit |
Bottom Line
If you are considering peptide therapy, ask the prescriber three questions. Which FDA bulks list category is this peptide on today? Which compounding pharmacy is supplying it, and from which API manufacturer? What human trial data — not animal data, not testimonials — supports the use being offered? If you do not get clean answers to all three, you are not being offered medicine.
“If a compound genuinely had the ability to burn fat, build muscle, regenerate tissue, and reverse aging without meaningful adverse effects, it would not need a podcast endorsement. It would survive clinical trials. It would earn FDA approval. It would simply be called medicine.”
— Dr. William Meller
References
- 1.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. July 2025.
- 2.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223–229.
- 3.Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899–908.
- 4.Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308.
- 5.Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45–53.
- 6.Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792–4797.
- 7.Stealth BioTherapeutics. FDA Accelerated Approval of FORZINITY (elamipretide) for Barth Syndrome. September 19, 2025.
- 8.Theratechnologies Inc. EGRIFTA WR FDA Approval. March 25, 2025.
- 9.Alliance for Pharmacy Compounding. Statement on Peptide Compounding. March 2024.
- 10.U.S. Food and Drug Administration. 503A Bulk Drug Substances Under Evaluation: Category 2 List. Updated April 15, 2026.
- 11.Frier Levitt. Regulatory Status of Peptide Compounding. April 2025.
- 12.Meller W. The Peptide Gold Rush: Snake Oil for the Biohacking Era. 2026.
- 13.Damon A. A Las Vegas Festival Promised Ways to Cheat Death. Two Attendees Left Fighting for Their Lives. ProPublica. July 30, 2025.
- 14.Damon A. Nevada Issues Fines for Peptide Injections at RAADFest, Where Two Women Fell Ill. ProPublica. March 13, 2026.
Dr. RP, MD is dual board-certified in Emergency Medicine and Critical Care Medicine and is the founder of Analog Precision Medicine, a precision medicine practice in Southern California. This article is for educational purposes only and does not constitute medical advice or establish a physician-patient relationship.
← Back to Blog